A Chinese medicine composition for treating simple obesity in children and its application

Abstract

The present invention relates to a traditional Chinese medicine composition for treating simple childhood obesity. The composition is prepared from the following raw materials in parts by weight: 4-8 parts of Atractylodes macrocephala, 4-8 parts of Rhizoma Alismatis, 3-7 parts of Lotus Leaf, 3-7 parts of Radix Scutellariae, 1-5 parts of Radix Ophiopogonis, and 1-5 parts of Pericarpium Citri Reticulatae. The present invention also provides the use of the composition in preparing a medicament for treating simple childhood obesity. The Atractylodes macrocephala is sweet and bitter, invigorates the spleen and replenishes qi, eliminates dampness and promotes diuresis, aids the spleen in transporting and transforming dampness, and reduces swelling, thus providing a tonifying effect throughout the entire prescription. The Rhizoma Alismatis is sweet, mild, and cold, and can dissipate dampness, expel heat, resolve turbidity, and reduce lipids. The two herbs are combined to eliminate heat and dampness, resolve turbidity, and reduce lipids, and together serve as the main herbal medicine. Lotus leaf, bitter and neutral in nature, enters the spleen and stomach meridians, clearing heat and transforming dampness, promoting the development of clear yang, and assisting the main herb in clearing stomach heat and dissipating dampness and turbidity. Scutellaria baicalensis clears heat and dries dampness, purging fire and detoxifying, enhancing the heat-clearing power of the entire formula and serving as an assistant herb. Ophiopogon japonicus nourishes the stomach and promotes fluid production, clearing the heart and relieving restlessness. Tangerine peel regulates qi and strengthens the spleen, drying dampness and resolving phlegm, assisting the main and assistant herb in removing dampness and heat, and serving as an adjuvant. Together, these herbs achieve the effects of clearing the stomach and purging heat, removing dampness and relieving swelling.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating simple obesity in children and application thereof. Background Art

[0002] Simple childhood obesity refers to a nutritional disorder in which children's long-term energy intake exceeds metabolic needs, resulting in excessive body fat accumulation and a weight exceeding a certain range. Children with simple obesity typically exhibit clinical symptoms such as overeating, lack of exercise, a high base weight, and a preference for sweets. Fat accumulation typically occurs in the face, shoulders, chest, and abdomen, significantly impacting children's daily lives and learning. Severely overweight children may also experience hypoxemia, cyanosis, and heart failure.

[0003] Chinese patent document CN 102988816A discloses a traditional Chinese medicine weight loss oral liquid for treating simple childhood obesity. Traditional Chinese medicine believes that spleen dysfunction and phlegm and blood stasis are the primary pathological mechanisms of simple childhood obesity. To this end, the present invention selects Chinese herbs—Chinese yam, longan, tangerine peel, green tangerine peel, fructus aurantii, bergamot, plum, lychee fruit, barley sprout, loofah, Fritillaria cirrhosa, polygala tenuifolia, rose flower, litchi kernel, cypress seed, and honey—that have the properties of invigorating the spleen and replenishing qi, dispelling phlegm, turbidity, and blood stasis. These are formulated into an oral liquid for patients to consume. Clinical trials at our hospital have shown an overall efficacy of 97%, resulting in significant weight loss in obese children, making the oral liquid worthy of clinical application.

[0004] Chinese patent document CN 105343824A discloses a traditional Chinese medicine composition for treating childhood obesity and its preparation method. The composition comprises, by weight, 6-12 parts of Pinellia ternata, 6-12 parts of dried tangerine peel, 6-12 parts of Chuanxiong rhizome, 9-15 parts of Citrus aurantium, 10-20 parts of wax gourd peel, 10-20 parts of processed Cyperus rotundus, 9-15 parts of Allium macrostemon, 10-20 parts of Poria cocos, 10-20 parts of Arisaema ciliata, 6-12 parts of loquat leaf, 5-15 parts of Pinellia ternata, 3-9 parts of Licorice root, 3-12 parts of Rhizoma Anemarrhenae, 6-12 parts of ginger, and 12-20 parts of honey. Compared with existing methods for treating childhood obesity, the traditional Chinese medicine composition of the present invention has a scientific formulation, significant efficacy, high safety, no side effects, low cost, and effectively prevents various acute and chronic diseases that may be caused by childhood obesity.

[0005] There are many traditional Chinese medicine compositions for treating simple childhood obesity, but they all have drawbacks, such as a plethora of medicinal ingredients, difficulty obtaining raw materials, high cost, and limited efficacy. Therefore, there is an urgent need for a safe and effective traditional Chinese medicine composition for treating simple childhood obesity that is effective, requires fewer ingredients, is practical, has high compliance, and is safe and effective. Summary of the Invention

[0006] The purpose of the present invention is to address the deficiencies in the prior art and provide a Chinese medicine composition for treating simple obesity in children and its application.

[0007] In a first aspect, the present invention provides a traditional Chinese medicine composition for treating simple obesity in children, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 4-8 parts of Atractylodes macrocephala, 4-8 parts of Alisma orientalis, 3-7 parts of lotus leaf, 3-7 parts of Scutellaria baicalensis, 1-5 parts of Ophiopogon japonicus, and 1-5 parts of dried tangerine peel.

[0008] As a preferred example, the Chinese medicine composition is prepared from the following raw materials in parts by weight: 5-7 parts of Atractylodes macrocephala, 5-7 parts of Alisma orientalis, 4-6 parts of lotus leaves, 4-6 parts of Scutellaria baicalensis, 2-4 parts of Ophiopogon japonicus, and 2-4 parts of dried tangerine peel.

[0009] As another preferred example, the Chinese medicine composition is prepared from the following raw materials in parts by weight: 6 parts of Atractylodes macrocephala, 6 parts of Alisma orientalis, 5 parts of lotus leaf, 5 parts of Scutellaria baicalensis, 3 parts of Ophiopogon japonicus, and 3 parts of dried tangerine peel.

[0010] As another preferred example, the dosage form of the Chinese medicine composition is decoction, granules, pills, powder, oral liquid, capsule or syrup.

[0011] In a second aspect, the present invention provides use of a traditional Chinese medicine composition in preparing a medicament for treating simple obesity in children.

[0012] As a preferred example, the simple obesity in children is simple obesity in children of the gastric heat and dampness obstruction type.

[0013] The advantages of the present invention are: it clears the stomach, eliminates heat, removes dampness and reduces swelling. Atractylodes macrocephala is sweet and bitter in the present invention, strengthens the spleen and replenishes qi, dries dampness and promotes diuresis, assists the spleen in transporting and transforming dampness, eliminates dampness and reduces swelling, and makes the whole prescription nourishing; Alismatis rhizome is sweet, mild and cold, penetrates dampness and eliminates heat, resolves turbidity and reduces lipids. The two herbs are combined to eliminate heat and dampness, resolve turbidity and reduce lipids, and are the main herbs. Lotus leaf is bitter and neutral in nature, enters the spleen and stomach meridians, clears heat and eliminates dampness, promotes the generation of clear yang, and assists the main herbs in clearing stomach heat and eliminating dampness and turbidity; Scutellaria baicalensis clears heat and dries dampness, eliminates fire and detoxifies, and enhances the heat-clearing power of the whole prescription, and is also the auxiliary herb; Ophiopogon japonicus benefits the stomach and produces body fluid, clears the heart and relieves restlessness; Tangerine peel regulates qi and strengthens the spleen, dries dampness and resolves phlegm, and assists the main and auxiliary herbs in eliminating dampness and heat, and are all adjuvants. The combination of these herbs achieves the functions of clearing the stomach, dredging heat, removing dampness and reducing swelling. The present invention is mainly used to treat obesity caused by stomach heat and dampness. Obesity, edema, dizziness, poor digestion, heaviness and fatigue in the limbs, laziness, thirst and excessive drinking, bad breath, constipation, red tongue with a greasy and slightly yellowish coating, slippery and rapid pulse, and sluggish fingerprints. The total effective rate in the treatment group and control group was 84.00% and 66.67%, respectively. The body mass index (BMI) in the treatment group decreased significantly after treatment, significantly better than that in the control group. The weight and waist circumference of the treatment group were significantly lower than those in the control group after treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1. Comparison of body weight of rats in the control group, high-dose group, low-dose group and model group on days 21-63-84 (g).

[0015] Figure 2 .Comparison of TC changes (mmol / L) in rats of the control group, high-dose group, low-dose group, and model group from day 63 to 84.

[0016] Figure 3 .Comparison of TG changes (mmol / L) in rats in the control group, high-dose group, low-dose group, and model group from day 63 to 84.

[0017] Figure 4 : Effect of Bai Ze Tang on the expression level of PRDM16 in brown fat. DETAILED DESCRIPTION

[0018] Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiments are only used to illustrate the present invention and are not used in limiting the scope of the present invention.In addition, should be understood that after reading the content of the present invention record, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall equally within the scope limited by the application's appended claims.

[0019] Example 1 Chinese medicine composition for treating simple obesity in children according to the present invention (I)

[0020] 6 parts of Atractylodes macrocephala, 6 parts of Rhizoma Alismatis, 5 parts of Lotus Leaf, 5 parts of Scutellaria baicalensis, 3 parts of Ophiopogon japonicus, and 3 parts of Citrus reticulatae.

[0021] Example 2 Chinese medicine composition for treating simple obesity in children according to the present invention (II)

[0022] 6 parts of Atractylodes macrocephala, 4 parts of Rhizoma Alismatis, 7 parts of Lotus leaf, 4 parts of Scutellaria baicalensis, 4 parts of Ophiopogon japonicus, and 3 parts of Citrus reticulatae.

[0023] Example 3 Chinese medicinal composition for treating simple obesity in children according to the present invention (III)

[0024] 4 parts of Atractylodes macrocephala, 8 parts of Rhizoma Alismatis, 4 parts of Lotus leaves, 6 parts of Scutellaria baicalensis, 3 parts of Ophiopogon japonicus, and 1 part of Citrus reticulatae.

[0025] Example 4 Chinese medicine composition for treating simple obesity in children according to the present invention (IV)

[0026] 8 parts of Atractylodes macrocephala, 5 parts of Rhizoma Alismatis, 6 parts of Lotus leaves, 5 parts of Scutellaria baicalensis, 1 part of Ophiopogon japonicus, and 5 parts of Citrus reticulatae.

[0027] Example 5 Chinese medicinal composition for treating simple obesity in children according to the present invention (V)

[0028] 5 parts of Atractylodes macrocephala, 7 parts of Rhizoma Alismatis, 5 parts of Lotus leaf, 3 parts of Scutellaria baicalensis, 5 parts of Ophiopogon japonicus, and 2 parts of Citrus reticulatae.

[0029] Example 6 Chinese medicine composition for treating simple obesity in children according to the present invention (VI)

[0030] 7 parts of Atractylodes macrocephala, 6 parts of Rhizoma Alismatis, 3 parts of Lotus leaf, 7 parts of Scutellaria baicalensis, 2 parts of Ophiopogon japonicus, and 4 parts of Citrus reticulatae.

[0031] Example 7 Chinese medicinal composition for treating simple obesity in children according to the present invention (VII)

[0032] 4 parts of Atractylodes macrocephala, 8 parts of Rhizoma Alismatis, 4 parts of Lotus leaves, 6 parts of Scutellaria baicalensis, 3 parts of Ophiopogon japonicus, and 1 part of Citrus reticulatae.

[0033] Example 8 Chinese medicinal composition for treating simple obesity in children according to the present invention (VIII)

[0034] 8 parts of Atractylodes macrocephala, 5 parts of Rhizoma Alismatis, 6 parts of Lotus leaves, 5 parts of Scutellaria baicalensis, 1 part of Ophiopogon japonicus, and 5 parts of Citrus reticulatae.

[0035] Example 9 Chinese medicinal composition for treating simple obesity in children according to the present invention (IX)

[0036] 5 parts of Atractylodes macrocephala, 7 parts of Rhizoma Alismatis, 5 parts of Lotus leaf, 3 parts of Scutellaria baicalensis, 5 parts of Ophiopogon japonicus, and 2 parts of Citrus reticulatae.

[0037] Example 10: Traditional Chinese medicine composition for treating simple obesity in children according to the present invention (X)

[0038] 7 parts of Atractylodes macrocephala, 6 parts of Rhizoma Alismatis, 3 parts of Lotus leaf, 7 parts of Scutellaria baicalensis, 2 parts of Ophiopogon japonicus, and 4 parts of Citrus reticulatae.

[0039] Example 11: Traditional Chinese medicine composition for treating simple obesity in children according to the present invention (XI)

[0040] 6 parts of Atractylodes macrocephala, 4 parts of Rhizoma Alismatis, 7 parts of Lotus leaf, 4 parts of Scutellaria baicalensis, 4 parts of Ophiopogon japonicus, and 3 parts of Citrus reticulatae.

[0041] Example 12 Animal Experiment

[0042] 1. Experimental Materials: Subjects and Housing: Forty healthy, three-week-old, SPF-grade male Sprague-Dawley (SD) rats weighing approximately 47-50 g were used. All rats were housed in separate cages, five per cage, at a room temperature of 22±1°C and a humidity of 40%-60%. They were exposed to natural light and had free access to water and food. They were maintained on a national standard rodent maintenance diet for one week.

[0043] 2. Main experimental instruments: 1) Precision electronic scale (SF-400A, Shanghai Zhirong Electronic Technology Co., Ltd.) 2) Vertical electrophoresis tank (Beijing Aikepu Instrument Factory) 3) Transfer tank (Beijing Aikepu Instrument Factory) 4) Electroporator (Beijing Aikepu Instrument Factory) 5) Electronic balance (Beijing Sartorius Instrument Co., Ltd.) 6) Centrifuge (Hunan Xiangyi Laboratory Instrument Development Co., Ltd.) 7) Microplate reader (Thermo) 8) Electric constant temperature blast drying oven (Shanghai Jinghong Laboratory Equipment Co., Ltd.) 9) Real-time fluorescence quantitative PCR instrument (ABI) 10 ) Fluorescence quantitative PCR tube (EXTRAGENE) 11) Micro-spectrophotometer (Hangzhou Aosheng Instrument Co., Ltd.) 12) Electric constant temperature water bath (Beijing Changfeng Instrument Co., Ltd.) 13) Microwave oven (LG) 14) Aquapro superpure water meter (Aikepu) 15) PCR instrument (Dongsheng Innovation Biotechnology Co., Ltd.) 16) Micropipette (Beijing Guangda Company) 17) Horizontal electrophoresis instrument (Beijing Junyi Oriental Electrophoresis Equipment Co., Ltd.) 18) UV analyzer (Beijing Junyi Oriental Electrophoresis Equipment Co., Ltd.)

[0044] 3. Main experimental reagents: 1) Phosphatase inhibitor (Biyuntian); 2) RIPA lysis (Biyuntian); 3) BCA protein concentration assay kit (Biyuntian); 4) TEMED (Amresco); 5) Acrylamide (Amresco); 6) Methylacrylamide (Amresco); 7) PVDF membrane (Millipore); 8) Tris-base (Biosharp); 9) Glycine (Biosharp); 10) Methanol (Sinopharm Chemical Reagent Co., Ltd.); 11) PBS (Biyuntian); 12) Protein marker (fermentas); 13) Rabbit polyclonal antibody against GAPDH (Hangzhou Xianzhi Biological Co., Ltd.); 14) Rabbit polyclonal antibody against PRDM16 (Abcam); 15) HRP-conjugated goat anti-rabbit secondary antibody (Wuhan Boster Biotechnology Co., Ltd.); 16) Skim milk powder (Wandashan Dairy Co., Ltd.); 17) ECL substrate solution (Thermo); 18) Developer / fixer kit (Tianjin Hanzhong Photographic Materials Factory); 19) Trizol (Aidlab); 20) SYBR Green PCR kit (Roche) 21) Primer sequences (Shanghai Jierui Biotechnology Co., Ltd.) 22) cDNA kit (Thermo)

[0045] 4. Experimental method: Grouping of experimental subjects: After one week of adaptive feeding, 40 rats were randomly divided into 4 groups, with 10 rats in each group. The control group continued to be fed with ordinary feed (the calorific value of ordinary feed was 16.7KJ / g), and the model group and the Bai Ze Tang (Example 1 of the present invention) intervention group were given high-fat feed respectively. The intervention group was gavaged with low and high concentrations of Bai Ze Tang solution at 3 pm every day (the low-dose group was 0.28 mg / kg; the high-dose group was 0.56 mg / kg), with a gavage volume of 0.4 ml / rat; the blank control group and the model group were gavaged with normal saline. Drinking water was free during the experiment. The rats were observed and recorded during the experiment. Experimental materials: In order to avoid the interference of irrelevant variables, all rats were fasted for 12 hours, and drinking water was not restricted during this period. The next morning, rats were weighed and anesthetized with an intraperitoneal injection of 2% sodium pentobarbital at a dose of 50 mg / kg body weight. Rats were sacrificed, and the abdominal cavity was opened with surgical scissors. Blood (10 ml) was collected from the abdominal aorta. The blood was then centrifuged in batches at 3500 rpm for 15 minutes in a 4°C incubator. A portion of the upper serum layer was collected for biochemical analysis, and the remainder was frozen for testing other parameters. Immediately after blood collection, the kidneys and surrounding white adipose tissue were completely removed from each rat, and fascia and other impurities were removed. Blood stains were washed with pre-chilled saline, dried with filter paper, and weighed. The tissues were snap-frozen in liquid nitrogen, transferred to enzyme-free Eppendorf tubes, and stored at -80°C for subsequent Western blotting, real-time PCR, and other experiments. Serum TC and TG levels were determined using an automated biochemical analyzer. PRDM16 expression: Western blotting was used to determine PRDM16 protein expression in white adipose tissue (WAT). Real-time PCR was used to determine changes in PRDM16 mRNA expression in WAT. Statistical analysis was performed using SPSS 26.0 software. Intergroup comparisons were performed using analysis of variance. P < 0.05 was considered statistically significant.

[0046] 5. Experimental Conclusions: Bai Ze Tang (of the present invention) slowed weight gain in obese rats and simultaneously reduced serum cholesterol and triglycerides. PRDM16 expression increased after administration of Bai Ze Tang, suggesting that the traditional Chinese medicine Bai Ze Tang may increase the production of brown fat, thereby increasing heat production and energy consumption in rats and thus reducing weight.

[0047] (1) Bai Ze Tang has the effect of slowing down the weight gain of obese rats. Figure 1 .

[0048] (2) Effects of Bai Ze Tang on TC and TG, see Figure 2 ; Figure 3 .

[0049] (3) The effect of Bai Ze Tang on the expression level of PRDM16 in brown fat is shown in Figure 4 .

[0050] Table 1: Comparison of PRDM16 in 84-day-old rats in the blank control group, high-dose group, and low-dose group

[0051]

[0052] The data do not follow a normal distribution, so the median is used to describe

[0053] Example 12 Clinical Trial

[0054] 1. Case source: The cases observed in this study were all from children aged 6-18 years old with simple obesity of gastric heat and dampness obstruction type who visited the pediatric outpatient clinic of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine between November 2022 and November 2023.

[0055] 2Diagnostic criteria:

[0056] Western medicine diagnostic standards: Refer to the description of simple obesity in children in the "Pediatrics" (edited by Xue Xindong) published by the People's Medical Publishing House and the "Guidelines for the Prevention and Control of Childhood Obesity (2021)" recommended by the National Health Commission's Disease Control Bureau as the diagnostic criteria for this disease.

[0057] (1) Body mass index (BMI): BMI ≥ 95th percentile of the same-age and same-sex group. The BMI value of school-age children with simple obesity refers to the national health industry standard "Screening for Overweight and Obesity in School-Age Children and Adolescents (WS / T586-2018)", see Table 2 for details.

[0058] Table 2. BMI critical values for obese children aged 6-18 years

[0059]

[0060] (2) Obesity: A measured weight that exceeds the standard weight by 20% to ≤30% is considered mild obesity, a weight that exceeds the standard weight by 30% to ≤50% is considered moderate obesity, and a weight that exceeds the standard weight by more than 50% is considered severe obesity. The standard weight for children aged 6-18 years is based on the 2014 National Physical Fitness Average Test Report, see Table 3 for details.

[0061] Table 3. Standard values of the 50th percentile of weight for children aged 6-18 years

[0062]

[0063] (3) Exclude the influence of secondary obesity: including but not limited to diseases such as Cushing's syndrome, hypothyroidism, growth hormone deficiency and pituitary dysfunction; as well as secondary obesity caused by long-term use of glucocorticoids, anti-epileptic or psychiatric drugs.

[0064] TCM Syndrome Differentiation Criteria: Based on the "Chinese Medicine Pediatrics" (Edited by Wang Shouchuan, published by the People's Medical Publishing House) and the "Clinical Multidisciplinary Diagnosis and Treatment Consensus on Obesity (2021 Edition)" issued by the Chinese Society of Endocrinology and other organizations, and according to the syndrome classification, combined with the physiological and pathological characteristics of children and clinical treatment experience, the diagnostic criteria for simple obesity in children with gastric heat and dampness obstruction type are formulated:

[0065] Main symptoms: obesity and edema (actual weight exceeds standard weight by 20%), poor appetite and increased hunger, and limb pain;

[0066] Secondary symptoms: thirst, frequent drinking, bad breath, dizziness, abdominal distension, and constipation;

[0067] Tongue: red tongue with greasy and slightly yellow coating;

[0068] Pulse: slippery and rapid.

[0069] Patients with two of the above main symptoms (physique obesity is a necessary condition), accompanied by two or more secondary symptoms, and whose tongue and pulse conditions are basically consistent, can be diagnosed with simple obesity of the stomach heat and dampness obstruction type.

[0070] 3 Inclusion criteria:

[0071] (1) Meet the diagnostic criteria for simple obesity in children according to Western medicine;

[0072] (2) Meet the TCM syndrome differentiation criteria for children with stomach heat and dampness obstruction;

[0073] (3) age range of 6-18 years;

[0074] (4) Basic information is complete;

[0075] (5) Have signed the informed consent form and can actively cooperate with the treatment according to the doctor's instructions.

[0076] 4 Exclusion criteria

[0077] (1) Including but not limited to patients with endocrine and metabolic diseases such as Cushing's syndrome, hypothyroidism, and growth hormone deficiency;

[0078] (2) Patients with pituitary diseases and pituitary dysfunction;

[0079] (3) People with secondary obesity caused by long-term use of glucocorticoids, anti-epileptic drugs and psychotropic drugs;

[0080] (4) Incomplete data affects subsequent investigation and determination of TCM syndrome types;

[0081] (5) Children with other serious underlying diseases and family medical history;

[0082] (6) Those with cardiopulmonary insufficiency and limited exercise;

[0083] (7) Those who are currently participating in or have received other related treatments or clinical trials within 3 months;

[0084] (8) Children with allergic constitution or allergy to the drugs used in this study.

[0085] 5. Rejection and shedding standards

[0086] (1) Poor compliance among subjects affects the judgment of effectiveness and clinical safety;

[0087] (2) During the observation and treatment period, the patient develops other chronic progressive diseases, or other complications and special physiological changes, making it unsuitable to continue with the subsequent trial;

[0088] (3) Subjects who no longer receive the prescribed medication and testing for any reason and are lost to follow-up;

[0089] (4) those who used other weight loss methods during the observation period;

[0090] 6 Research methods and results: Through a prospective, randomized controlled research method, 120 children aged 6-18 years with simple obesity admitted between November 2022 and November 2023 were randomly divided into a treatment group and a control group. The treatment group was given Baize Decoction (one dose per day for children aged 6-18 years, taken twice a day in the morning and evening (Example 1 of the present invention is made into granules), taken with water) combined with aerobic exercise treatment, and the control group was given aerobic exercise treatment. After 3 months of treatment, the total effective rates of the treatment group and the control group were 84.00% and 66.67%, respectively. The reduction in body mass index (BMI) in the treatment group after treatment was significantly better than that in the control group. After treatment, the weight and waist circumference of the treatment group were significantly smaller than those of the control group.

[0091] Table 4: Comparison of clinical efficacy between the two groups of patients

[0092] Number of cases cure Significantly effective invalid Total efficiency Treatment group 60 29 22 9 85.0％ control group 60 18 21 21 65.0％

[0093] Note: The total effective rate refers to the percentage of cured and significantly effective cases in the total number of cases.

[0094] Table 5: Changes in BMI and WHtR in the two groups of patients before and after treatment

[0095]

[0096] Note: Compared with the control group*P<0.05, compared with the self before treatment △ P<0.05

[0097] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention. These improvements and supplements should also be regarded as the scope of protection of the present invention.

Claims

1. Use of a Chinese medicine composition in preparing a medicament for treating simple obesity in children of gastric heat and dampness obstruction type, characterized in that: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 4-8 parts of Atractylodes macrocephala, 4-8 parts of Rhizoma Zedoariae, 3-7 parts of lotus leaves, 3-7 parts of Scutellaria baicalensis, 1-5 parts of Radix Ophiopogonis, and 1-5 parts of dried tangerine peel.

2. The use according to claim 1, characterized in that The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 5-7 parts of Atractylodes macrocephala, 5-7 parts of Rhizoma Zedoariae, 4-6 parts of lotus leaves, 4-6 parts of Scutellaria baicalensis, 2-4 parts of Radix Ophiopogonis, and 2-4 parts of dried tangerine peel.

3. The use according to claim 1, characterized in that The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 6 parts of Atractylodes macrocephala, 6 parts of Rhizoma Alismatis, 5 parts of Lotus leaf, 5 parts of Scutellaria baicalensis, 3 parts of Radix Ophiopogonis, and 3 parts of Pericarpium Citri Reticulatae.

Images